Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

orthoPROTACS

Financiado

Cerrado

Design of orthogonal molecular probes targeting engineered von Hippel Lindau VH...

Design of orthogonal molecular probes targeting engineered von Hippel Lindau VHL E3 ubiquitin ligase for the control of intracellular protein levels The development of potent, selective and cell-permeable small molecule chemical probes as tools to interrogate and modulate cellular functions of the human proteome is a rapidly growing field. The direct manipulation of protein in... ver más

07/04/2015

UNIVDUN

222K€

Presupuesto del proyecto: 222K€

Líder del proyecto

UNIVERSITY OF DUNDEE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-04-07 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVDUN

0.00€ | Lider

Proyectos interesantes

DELETER

Medical Technol...

Biotechnology

213K€ Cerrado

PREDICT

Medical Technol...

Chemical Engine...

213K€ Cerrado

BFU2008-01108

Medical Technol...

Biotechnology

121K€ Cerrado

DRUGE3CRLS

Medical Technol...

Biotechnology

1M€ Cerrado

ANCHOR E3s

Medical Technol...

Biotechnology

183K€ Cerrado

pVHL-CRL

Medical Technol...

Biotechnology

200K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSITY OF DUNDEE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 222K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The development of potent, selective and cell-permeable small molecule chemical probes as tools to interrogate and modulate cellular functions of the human proteome is a rapidly growing field. The direct manipulation of protein intracellular level and activity using small molecules has enormous potential to elucidate and validate new drug targets and therapeutics tools. In the last decade, researchers have discovered an alternative method to directly control the level of protein components inside the cell without altering its DNA or RNA. This approach uses chemicals known as PROteolysis TArgeting Chimeric moleculeS (PROTACS) which exploit the ubiquitin/proteasome pathway to direct the intracellular degradation of any Proteins Of Interest (POI) by linking a section that mimics the recognition? motif of the natural substrate to one that binds the POI. PROTACS enable recruitment of any POI to an E3 Ubiquitin ligase. To date, the strategy has displayed some success, however much improvement is still required to known compounds to make this approach widely useful, and althernative new strategies need to be developed to add to the current arsenal of chemical tools. In preliminary work leading to this proposal the Ciulli Lab. (University of Cambridge) has discovered and characterised the first drug-like small molecules that target the Von Hippel Lindau (VHL) E3 Ubiquitin Ligase and disrupt its interaction with substrate Hypoxia Inducible Factor (HIF) with low micromolar affinities. Harnessing this knowledge, and using these inhibitors as starting points, the proposed research will develop a multidisciplinary approach combining medicinal chemistry, protein engineering with biophysical studies and concerning designed, mutated/engineered VHL-ligand pairs that could ultimately be exploited as an orthogonal approach to modulate the level of any protein inside the cell.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores